Trial Profile
Retrospective cohort study of correlation between immune check point molecular inhibitor and response factor, side effect, and post treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Aug 2020 Results published in the Anticancer Research
- 10 Sep 2019 Multivariable analysis results elucidated with a nomogram were presented at the 20th World Conference on Lung Cancer.
- 10 Sep 2019 Results assessing prediction of patients outcomes from patients charecteristics (n=128) presented at the 20th World Conference on Lung Cancer.